Bank Julius Baer & Co’s Neurocrine Biosciences NBIX Stock Holding History

Bank Julius Baer & Co’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.24M	Sell	9,618 -2,295	-19%	-$305K	﹤0.01%	364
2025 Q4	$1.68M	Buy	+11,913	New	+$1.73M	﹤0.01%	336
2024 Q1	–	Sell	-1,084	Closed	-$143K	–	555
2023 Q4	$143K	Sell	1,084 -13	-1%	-$1.5K	﹤0.01%	421
2023 Q3	$123K	Buy	+1,097	New	+$116K	﹤0.01%	408
2023 Q1	–	Sell	-2,474	Closed	-$295K	–	604
2022 Q4	$295K	Buy	2,474 +794	+47%	+$93K	﹤0.01%	388
2022 Q3	$178K	Buy	+1,680	New	+$170K	﹤0.01%	412
2022 Q2	–	Sell	-150	Closed	-$14K	–	621
2022 Q1	$14K	Buy	+150	New	+$12.7K	﹤0.01%	565

Other funds holding NBIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank Julius Baer & Co's NBIX Position: Q1 2026 in Review

Bank Julius Baer & Co reduced its Neurocrine Biosciences (NBIX) stake by 19% in Q1 2026, selling an estimated $305K and leaving 9,618 shares worth $1.24M. The position accounts for ﹤0.01% of the portfolio, ranked #364.

Bank Julius Baer & Co first reported a position in NBIX in Q1 2022 and has held it in 7 quarters since. The position peaked at $1.68M in Q4 2025. 696 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

Bank Julius Baer & Co held 9,618 shares of Neurocrine Biosciences worth $1.24M as of Q1 2026.
Bank Julius Baer & Co sold 2,295 Neurocrine Biosciences shares in Q1 2026, an estimated $305K.
Neurocrine Biosciences made up ﹤0.01% of Bank Julius Baer & Co's portfolio in Q1 2026, its #364 holding.
Bank Julius Baer & Co first reported a position in Neurocrine Biosciences in Q1 2022 and has held it in 7 quarters since.
Bank Julius Baer & Co's Neurocrine Biosciences position peaked at $1.68M in Q4 2025.
696 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Bank Julius Baer & Co's 13F filing for Q1 2026, filed 5 May 2026.